About EUROIMMUN

Autoimmune diagnostics
Infection diagnostics
Allergy diagnostics
Antigen detection
Molecular diagnostics
Automation
EUROIMMUN is one of the leading manufacturers of medical laboratory diagnostics worldwide and stands for innovation. Around 2000 employees in twelve countries develop, produce and sell test systems for the diagnosis of diseases, and software and automation solutions for the performance and evaluation of these assays. Laboratories in over 150 countries use EUROIMMUN products for the diagnosis of autoimmune and infectious diseases and allergies, and to perform genetic analyses. The company was founded 1987 from the University of Luebeck (Schleswig-Holstein, Germany). In the business year 2015, the group turnover amounted to more than 205 million euros.

The enterprise has extensive expertise in the fields of immunology, cell biology, histology, biochemistry and molecular biology. EUROIMMUN is based on state-of-the-art, partly patented production processes and microanalysis techniques.

Among the initial pioneer achievements of the company was the development of the BIOCHIP (1983). Today, EUROIMMUN has at its disposal virtually fully automated BIOCHIP fragmentation and production devices, which were designed and produced in-house and are now in use worldwide.

Furthermore, EUROIMMUN commands a broad technology base which has enabled it to initiate and promote fundamental, new developments in medical laboratory diagnostics. Examples are the molecular biological synthesis of designer antigens, computer-aided immunofluorescence microscopy (CAIFM) and the development of multi-parametric microarrays for the identification of genetic polymorphisms, tumours or pathogenic agents, amongst others.

Great expertise and ongoing training are essential for the use and distribution of the products. Every year, the EUROIMMUN Academy receives almost 1000 customers from over 50 countries, providing training for customers, field staff, and employees from all EUROIMMUN subsidiaries. Moreover, there are training laboratories in several countries. The accredited Institute for Quality Assurance, an institution of the company, organises quality assessment schemes and thus helps to maintain the high quality standard of external laboratories.

The Institute for Experimental Immunology, another EUROIMMUN institution, is dedicated to basic research. The institute also cooperates with universities, clinics and renowned research institutions from all over the world. These cooperations have resulted in a large number of diploma and doctoral theses. EUROIMMUN is ISO certified (EN ISO 9001:2008, EN ISO 13485:2012, ISO 13485/CMDCAS).

A large share of the company’s success can be attributed to the associated reference laboratory, which offers a fast and differentiated diagnosis to the EUROIMMUN customers and clarifies several hundreds of patient samples with difficult constellations every day.

EUROIMMUN meets its needs for qualified personnel not only through its presence at recruitment and trade fairs and advertisements, but also through its own training program. Alongside the vocational school, the apprentices and trainees are offered a comprehensive practical and theoretical program and intensive mentoring in the work routine. At present, the company employs 60 trainees and around 2000 persons worldwide. Women represent nearly 60% of staff and thus the majority. 912 employees have an academic background, 134 of them hold a doctoral degree.

The atmosphere in the company is productive and characterised by openness and mutual respect. EUROIMMUN offers unlimited employment contracts. All employees
can participate in the company’s success as shareholders, benefit from the company’s pension scheme, receive bonuses for excellent performance, and have the possibility to participate in regular trainings. The company’s restaurant offers an excellent choice of food. Day care and an after-school club is provided for the employees’ children.

EUROIMMUN in figures

<table>
<thead>
<tr>
<th>Year</th>
<th>Event</th>
<th>Figures</th>
</tr>
</thead>
<tbody>
<tr>
<td>1987</td>
<td>Founded in Luebeck, Germany</td>
<td></td>
</tr>
<tr>
<td>205 M</td>
<td>Euros annual Group turnover in 2015</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Offices in Germany</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Subsidiaries in other countries</td>
<td></td>
</tr>
<tr>
<td>242</td>
<td>Proprietary/in-licensed IP rights</td>
<td></td>
</tr>
<tr>
<td>2096</td>
<td>Employees worldwide</td>
<td></td>
</tr>
<tr>
<td>953</td>
<td>University graduates</td>
<td></td>
</tr>
<tr>
<td>142</td>
<td>Employees with doctoral degree</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>Apprentices</td>
<td></td>
</tr>
</tbody>
</table>

Recent product innovations

- **Unique test system for the diagnosis of infections with tropical pathogens such as Zika, dengue or chikungunya virus**: e.g. Anti-Zika Virus ELISA – Highly specific diagnosis of Zika virus infections and, in addition, exclusion of cross reactions with other flaviviruses through the use of the virus-specific NS1 protein
- **Comprehensive selection of neurology parameters**: Diagnosis and differentiation of autoimmune and neurodegenerative diseases
- **DPA-Dx Profiles Pollen, Insect Venoms, Peanut, Paediatrics**: Molecular allergy diagnostics based on individually purified allergen components (defined partial allergens, DPA) for differential diagnosis of allergic sensitisation patterns
- **EUROArray HPV + STI**: Molecular diagnostic tests for the detection and typing of all relevant HPV types (18 high-risk and 12 low-risk HPV: EUROArray HPV) and for the detection of 11 sexually transmitted pathogens (EUROArray STI) in only one reaction
- **Trend-setting markers for nephrology**: Anti-THSD7A optimally complements anti-PLAR2R in the non-invasive diagnosis of primary membranous nephropathy, and serum uromodulin as early indicator of kidney function loss
- **EUROLINE ANA Profile 23 (IgG)**: Multiplex test for confirmation and differentiation of all ANA patterns in accordance with ICAP (www.anapatterns.org)
- **EUROLabWorkstation and Mergite!**: Efficient and user-friendly full automation for ELISA or IIFT, including the novel Mergite! technology for quick and contamination-free washing of IIFT slides (also available as stand-alone version)
- **EUROPATTERN Microscope and software**: Automated microscopy and modern interpretation of diagnostic results at the PC screen (ANA, ANCA, CLIFT, tissue and transfected/infected cells, also as mosaic) and pattern recognition with titer determination
Publications with EUROIMMUN’s participation (2015)


Scientific presentations


18. Schlumberger W. **Autoantibodies against phospholipase-A2 receptors in membranous nephropathy.** Seminar, Unità Operativa Complessa di Nefrologia, Università Cattolica, Italy (2015).

19. Stöcker W. **Comprehensive diagnostics of neurology-related autoantibodies using authentic recombinant autoantigens.** All-Russia XX Conference on Neuroimmunology, Multiple Sclerosis, St. Petersburg, Russia (2015).

20. Stöcker W. **Discovery of new target antigens in autoimmune encephalitis applying histoimmune precipitation.** EUROIMMUN Autoimmunity Tripartite Forum 2015 (Tripartite: Clinic, Laboratory, and EUROIMMUN), Beijing, China (2015).

21. Stöcker W. **Revealing new forms of autoimmune encephalitis associated with autoantibodies against neuron specific Na+/K-ATPase ATP1A3, neurochondrin, flotillin and inositoltriphosphate-receptors.** Oral presentation at the Beijing Union Medical College Hospital, Beijing, China (2015).

New patents

1. Meyer W, Scheper T, Kaffka R. **Device and method for storing and transporting a bodily fluid.** German and International patent application DE 10 2013 008 468.7 (filed 2013) and WO 2014/173657 (filed 2014).


7. Feirer C, Pannhoff H. **Calibration standard for a device for image-based representation of biological material.** German and International patent application DE 10 2013 021 097 (filed 2013) and WO 2015/90534 (filed 2014).


11. Stöcker W. **Improved device and method for reactions between a solid and a liquid phase.** German and International patent application DE 10 2014 001 481 (filed 2014) and WO 2015/62715 (filed 2014).